LON:DNL

Diurnal Group Share Forecast, Price & News

GBX 68.25
-1.75 (-2.50 %)
(As of 04/22/2021 04:06 PM ET)
Add
Compare
Today's Range
67
Now: GBX 68.25▼
69.90
50-Day Range
55
MA: GBX 71.51▼
89
52-Week Range
27
Now: GBX 68.25▼
97.98
Volume286,964 shs
Average Volume493,432 shs
Market Capitalization£94.42 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe. It also develops Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.
Diurnal Group logo

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolLON:DNL
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.diurnal.co.uk
Phone+44-29-20682069
Employees29
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.77
Current Ratio7.46
Quick Ratio6.79

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales£6.38 million
Price / Sales14.80
Cash FlowGBX 15.44 per share
Price / Cash Flow4.42
Book ValueGBX 18.10 per share
Price / Book3.77

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares138,337,000
Market Cap£94.42 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Diurnal Group (LON:DNL) Stock Price Up 0.7%
April 17, 2021 |  americanbankingnews.com
Companies Like Diurnal Group (LON:DNL) Can Afford To Invest In Growth
March 23, 2021 |  finance.yahoo.com
Diurnal Reports Widened Loss In First Half Despite Revenue Growth
February 23, 2021 |  lse.co.uk
UPDATE: Diurnal Loss Widens In First Half; Signs Chronocort Deal
February 23, 2021 |  lse.co.uk
When Can We Expect A Profit From Diurnal Group plc (LON:DNL)?
February 6, 2021 |  finance.yahoo.com
Diurnal Inks Licence Agreement For Alkindi With Citrine Medicine
January 27, 2021 |  lse.co.uk
Diurnal Group PLC : Agreement with Eton for Alkindi extended to Canada
January 14, 2021 |  markets.businessinsider.com
What Kind Of Investors Own Most Of Diurnal Group plc (LON:DNL)?
January 1, 2021 |  finance.yahoo.com
Male Hypogonadism Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
December 29, 2020 |  marketwatch.com
5 Biopharma Stocks Making Big Moves Monday
December 14, 2020 |  msn.com
Key Things To Understand About Diurnal Group's (LON:DNL) CEO Pay Cheque
November 26, 2020 |  finance.yahoo.com
Diurnal Raises GBP8 Million For Product Development, Commercialisation
October 9, 2020 |  lse.co.uk
Hardman & Co Research: Diurnal (DNL): And then there were three
September 30, 2020 |  uk.finance.yahoo.com
Diurnal Grp Share Chat
September 8, 2020 |  lse.co.uk
The Diurnal Group (LON:DNL) Share Price Has Gained 68% And Shareholders Are Hoping For More
September 1, 2020 |  finance.yahoo.com
BRIEF-Diurnal Group Says Well-Positioned To Minimise Impact Of COVID-19
April 15, 2020 |  www.reuters.com
Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
March 30, 2020 |  www.finanznachrichten.de
Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle
March 27, 2020 |  finance.yahoo.com
BRIEF-Diurnal Group Has Raised About £11.2 Mln (Before Expenses) In Aggregate
March 26, 2020 |  www.reuters.com
UPDATE: Diurnal Placing Raises GBP11 Million For Drug Development
March 6, 2020 |  www.lse.co.uk
See More Headlines

MarketRank™

Overall MarketRank™

0.56 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 68.25
-1.75 (-2.50 %)
(As of 04/22/2021 04:06 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DNL News and Ratings via Email

Sign-up to receive the latest news and ratings for DNL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Diurnal Group (LON:DNL) Frequently Asked Questions

What stocks does MarketBeat like better than Diurnal Group?

Wall Street analysts have given Diurnal Group a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Diurnal Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Diurnal Group's earnings last quarter?

Diurnal Group plc (LON:DNL) released its quarterly earnings results on Tuesday, September, 15th. The company reported ($4.30) earnings per share for the quarter, topping analysts' consensus estimates of ($6.70) by $2.40.
View Diurnal Group's earnings history.

How has Diurnal Group's stock been impacted by COVID-19?

Diurnal Group's stock was trading at GBX 34 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DNL stock has increased by 100.7% and is now trading at GBX 68.25.
View which stocks have been most impacted by COVID-19.

Who are Diurnal Group's key executives?

Diurnal Group's management team includes the following people:
  • Dr. Martin Whitaker B.Sc., BSc, Ph.D., CEO & Exec. Director
  • Mr. Richard Edward Bungay A.C.A., B.Sc., BSc, ACA, CFO, Company Sec. & Director (Age 52, Pay $364k)
  • Prof. Richard Ross, Chief Scientific Officer & Exec. Director
  • Mr. Daniel Margetson, Director of Chemistry, Manufacturing & Controls

Who are some of Diurnal Group's key competitors?

Some companies that are related to Diurnal Group include Amryt Pharma (AMYT), The Supreme Cannabis (FIRE), ICC Labs (ICC), The Green Organic Dutchman (TGOD), ESSA Pharma (EPI), Venture Life Group (VLG), Shield Therapeutics (STX), WeedMD (WMD), Delta 9 Cannabis (NINE), Science in Sport (SIS), Acerus Pharmaceuticals (ASP), The Flowr (FLWR), BioSyent (RX), Medexus Pharmaceuticals (MDP) and Viridium Pacific Group (VIR).
View all of DNL's competitors.

What other stocks do shareholders of Diurnal Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diurnal Group investors own include Allena Pharmaceuticals (ALNA), Abercrombie & Fitch (ANF), Ampliphi Biosciences (APHB), Cerecor (CERC), Revolution Lighting Technologies (RVLT), Spero Therapeutics (SPRO), SRC Energy (SRCI), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF) and AcelRx Pharmaceuticals (ACRX).

What is Diurnal Group's stock symbol?

Diurnal Group trades on the London Stock Exchange (LON) under the ticker symbol "DNL."

How do I buy shares of Diurnal Group?

Shares of DNL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Diurnal Group's stock price today?

One share of DNL stock can currently be purchased for approximately GBX 68.25.

How much money does Diurnal Group make?

Diurnal Group has a market capitalization of £94.42 million and generates £6.38 million in revenue each year.

How many employees does Diurnal Group have?

Diurnal Group employs 29 workers across the globe.

What is Diurnal Group's official website?

The official website for Diurnal Group is www.diurnal.co.uk.

Where are Diurnal Group's headquarters?

Diurnal Group is headquartered at Heath Park, CARDIFF, CF14 4UJ, United Kingdom.

How can I contact Diurnal Group?

Diurnal Group's mailing address is Heath Park, CARDIFF, CF14 4UJ, United Kingdom. The company can be reached via phone at +44-29-20682069.


This page was last updated on 4/22/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.